Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

"A PHASE 3 RANDOMIZED STUDY COMPARING PERIOPERATIVE NIVOLUMAB VS. OBSERVATION IN PATIENTS WITH LOCALIZED RENAL CELL CARCINOMA UNDERGOING NEPHRECTOMY (PROSPER RCC)."

Intervention/treatment:
OPDIVO
Medical condition:
RENAL CELL CARCINOMA
Protocol code:
REC.4 / EA8143
Control number:
220796
Status:
Active, not recruiting
Approved:
October 30, 2018
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT03055013
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Study Statistician
Organization
ECOG-ACRIN Statistical Office
Phone:
617-632-3012
Sponsor
QUEENS UNIVERSITY

Locations

Alberta

Arthur J E Child Comprehensive Cancer Centre
Calgary, Alberta, T2N 5G2
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2

Manitoba

CancerCare Manitoba
Winnipeg, Manitoba, R3E 0V9

New Brunswick

The Moncton Hospital
Moncton, New Brunswick, E1C 6Z8

Nova Scotia

QEII Health Sciences Centre/Nova Scotia Health Authority
Halifax, Nova Scotia, B3H 2Y9

Ontario

Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, L8V 5C2
Kingston Health Sciences Centre
Kingston, Ontario, K7L 2V7
London Regional Cancer Program
London, Ontario, N6A 4L6
Niagara Health System-Saint Catharines General
Saint Catharines, Ontario, L2S 0A9
Odette Cancer Centre- Sunnybrook Health Sciences Centre
Toronto, Ontario, M4N 3M5
Saint Joseph's Healthcare Charlton Campus
Hamilton, Ontario, L8N 4A6
University Health Network-Princess Margaret Hospital
Toronto, Ontario, M5G 2M9
Windsor Regional Cancer Centre
Windsor, Ontario, N8W 2X3

Quebec

Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
Sherbrooke, Quebec, J1H 5N4
CHUM - Centre Hospitalier de l'Universite de Montreal
Montreal, Quebec, H2X 3E4

Results

See the results from the trial NCT03055013. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?